Amylose
Veille bibliographique : Amylose
Les articles sont classés du plus ancien au plus récent, n’hésitez pas à utiliser la barre de recherche pour filtrer les résultats par date par exemple.
| Yilmaz S et al. Tocilizumab in the treatment of patients with AA amyloidosis secondary to familial Mediterranean fever Rheumatology (Oxford). 2015 Mar;54(3):564-5 | Lire le résumé |
| Hamanoue S et al. Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever. Mod Rheumatol. 2016 Jul;26(4):610-3 | Lire le résumé |
| Lane T et al.Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2017 Sep;24(3):189–93. | Lire le résumé |
| Blank N, Hegenbart U, Dietrich S, Brune M, Beimler J, Röcken C, et al. Obesity is a significant susceptibility factor for idiopathic AA amyloidosis. Amyloid. 2018 Jan 2;25(1):37–45. | Lire le résumé |
| Esatoglu SN, Hatemi G, Ugurlu S, Gokturk A, Tascilar K, Ozdogan H. Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study. Medicine. 2017 Aug;96(34):e7859. Stankovic Stojanovic K, Georgin-Lavialle S, Poitou C, Buob D, Amselem S, Grateau G, et al. AA amyloidosis is an emerging cause of nephropathy in obese patients. European Journal of Internal Medicine. 2017 Apr;39:e18–20. | Lire le résumé Complément de résumé |
| Okuda Y,Yamada T, Ueda M, Ando Y. First Nationwide Survey of 199 Patients with Amyloid A Amyloidosis in Japan. Internal Medicine [Internet]. 2019 [cited 2018 Oct 29]; Available from: https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_1099-18/_article | Lire le résumé |
| , Calderaro JLetouzé E, Bayard Q, Boulai A, Renault V, Deleuze J-F, et al. Systemic AA Amyloidosis Caused by Inflammatory Hepatocellular Adenoma. New England Journal of Medicine. 2018 Sep 20;379(12):1178–80. | Lire le résumé |
| Kisla Ekinci RM, Balci S, Bisgin A, Hershfield M, Atmis B, Dogruel D, et al. Renal Amyloidosis in Deficiency of Adenosine Deaminase 2: Successful Experience With Canakinumab. Pediatrics. 2018 Nov;142(5):e20180948 Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, et al. Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2. New England Journal of Medicine. 2014 Mar 6;370(10):911–20 Batu ED, Karadag O, Taskiran EZ, Kalyoncu U, Aksentijevich I, Alikasifoglu M, et al. A Case Series of Adenosine Deaminase 2-deficient Patients Emphasizing Treatment and Genotype-phenotype Correlations. The Journal of Rheumatology. 2015 Aug;42(8):1532–4 | Lire le résumé |
| 1. Sarıtaş H, Sendogan DO, Kumru G, Sadioglu RE, Duman N, Erturk S, et al. Long-term Results of Kidney Transplantation in Patients With Familial Mediterranean Fever and Amyloidosis. Transplant Proc [Internet]. août 2019 [cité 26 août 2019] 2. Sendogan DO, Saritas H, Kumru G, Eyupoglu S, Sadioglu RE, Tuzuner A, et al. Outcomes of Canakinumab Treatment in Recipients of Kidney Transplant With Familial Mediterranean Fever: A Case Series. Transplant Proc [Internet]. août 2019 [cité 26 août 2019] | Lire le résumé |
| Brunger AF, Nienhuis HLA, Bijzet J, Hazenberg BPC. Causes of AA amyloidosis: a systematic review. Amyloid. 2 janv 2020;27(1):1‑12. | Lire le résumé |
| Sikora J, Kmochová T, Mušálková D, Pohludka M, Přikryl P, Hartmannová H, et al. A mutation in the SAA1 promoter causes hereditary amyloid A amyloidosis. Kidney Int. sept 2021;S008525382100867X. | Lire le résumé |
| Khellaf G, Benziane A, Kaci L, Ait-Idir D, Missoum S, Benabadji M. Renal involvement in familial Mediterranean fever in an Algerian population. Clin Nephrol. 2023 Apr;99(4):172-179. doi: 10.5414/CN110930. PMID: 36734158.. (PubMed) | Lire le résumé |
| Oliveira-Silva C, Marques N, Pinho A, Poínhos R, Bergantim R, Nunes AT, Sampaio S, Rodrigues-Pereira P, Silva R, Praça A, Frazão J, Pestana M, Tavares I. Lessons from Four Decades of Systemic Amyloidosis with Renal Involvement. Nephron. 2023;147(3-4):158-169. doi: 10.1159/000525675. Epub 2022 Sep 12. PMID: 36096123. | Lire le résumé |
| Fontana M, Gilbertson J, Verona G, Riefolo M, Slamova I, Leone O, Rowczenio D, Botcher N, Ioannou A, Patel RK, Razvi Y, Martinez-Naharro A, Whelan CJ, Venneri L, Duhlin A, Canetti D, Ellmerich S, Moon JC, Kellman P, Al-Shawi R, McCoy L, Simons JP, Hawkins PN, Gillmore JD. Antibody-Associated Reversal of ATTR Amyloidosis-Related Cardiomyopathy. N Engl J Med. 2023 Jun 8;388(23):2199-2201. doi: 10.1056/NEJMc2304584. PMID: 37285532 | Lire le résumé |
| Rauf MU, Hawkins PN, Cappelli F, Perfetto F, Zampieri M, Argiro A, et al. Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis. Eur Heart J. 25 juin 2023;44(24):2187‑98. | Lire le résumé |
| Lopes J, Peixoto M, Antunes E, Silva I, Caridade S. Secondary Amyloidosis and Common Variable Immunodeficiency: A Rare Association. Cureus. nov 2022;14(11):e31976. Delplanque M, Galicier L, Oziol E, Ducharme-Bénard S, Oksenhendler E, Buob D, et al. AA Amyloidosis Secondary to Primary Immune Deficiency: About 40 Cases Including 2 New French Cases and a Systematic Literature Review. J Allergy Clin Immunol Pract. févr 2021;9(2):745-752.e1. | Lire le résumé |
| Thimm A, Carpinteiro A, Oubari S, Papathanasiou M, Kessler L, Rischpler C, et al. Corneal confocal microscopy identifies corneal nerve loss and increased Langerhans cells in presymptomatic carriers and patients wit hereditary transthyretin amyloidosis. J Neurol. juill 2023;270(7):3483‑91 | Lire le résumé |
| Ioannou A, Porcari A, Patel RK, Razvi Y, Sinigiani G, Martinez-Naharro A, et al. Rare Forms of Cardiac Amyloidosis: Diagnostic Clues and Phenotype in Apo AI and AIV Amyloidosis. Circ Cardiovasc Imaging. juill 2023;16(7):523‑35. | Lire le résumé |
| Shimazaki C, Matsui-Maegawa S, Kimoto-Matsumura Y, Ota-Kuwabara S, Ide D, Fuchida SI, et al. The serum level of plasmin-alpha2 plasmin inhibitor complex (PIC) is useful for differentiating cardiac light chain amyloidosis from transthyretin amyloidosis. Br J Haematol. sept 2023;202(6):1209‑12 | Lire le résumé |
| Socie P, Benmalek A, Cauquil C, Piekarski E, Kounis I, Eliahou L, et al. Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis. Amyloid. 3 juill 2023;30(3):303‑12 | Lire le résumé |
| Dolkar T, Mann H, Salahuddin M, Spitalewitz S, Shein L. Renal Amyloid-Associated (AA) Amyloidosis in a Sickle Cell Patient: A Case Report and Literature Review. Cureus. mars 2023;15(3):e36608 | Lire le résumé |
| Bektas M, Koca N, Oguz E, Sari S, Dagci G, Ince B, et al. Characteristics and course of patients with AA Amyloidosis: single center experience with 174 patients from Turkey. Rheumatol Oxf Engl. 20 sept 2023;kead465 | Lire le résumé |
| Schwarz C, Georgin-Lavialle S, Lombardi Y, Marion O, Jambon F, Legendre C, et al. Kidney Transplantation in Patients With AA Amyloidosis: Outcomes in a French Multicenter Cohort. Am J Kidney Dis Off J Natl Kidney Found. 22 sept 2023;S0272-6386(23)00834-X | Lire le résumé |
| Steinebrei M, Baur J, Pradhan A, Kupfer N, Wiese S, Hegenbart U, et al. Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis. Nat Commun. 22 nov 2023;14(1):7623. | Lire le résumé |
| Brunger AF, Nienhuis HLA, Bijzet J, Zonneveld-Huijssoon E, Sanders JSF, Legger GE, et al. AA amyloidosis in a father and daughter as complication of PSTPIP1-associated myeloid-related proteinemia inflammatory (PAMI) syndrome. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 23 oct 2023;1‑3 | Lire le résumé |
| Marchi F, Kessler C, Distefano D, Terzi Di Bergamo L, Fumagalli L, Averaimo M, et al. Prevalence of amyloid in ligamentum flavum of patients with lumbar spinal stenosis. Amyloid. 2 oct 2023;30(4):416‑23 | Lire le résumé |
| Orchard GE. Gout With Associated Cutaneous AA Amyloidosis: A Case Report and Review of the Literature. Br J Biomed Sci. 2023;80:11442 | Lire le résumé |
| Bourguiba R, Terré A, Savey L, Oziol E, Hanslik T, Kahn JE, et al. Symptomatic SARS-CoV2 infection associated with high mortality in AA amyloidosis. Amyloid. 21 déc 2023;1‑3. | Lire le résumé |
| Alehashemi S, Dasari S, Metpally A, Uss K, Castelo‐Soccio LA, Heller T, et al. Anakinra‐Associated Systemic Amyloidosis. Arthritis Rheumatol. janv 2024;76(1):100‑6 | Lire le résumé |
| Ullah N, Bin Naeem S, Jhatial MA, Majeed MA, Saeed SM, Muzaffar S, et al. Acute Tubulointerstitial Nephritis and Secondary Renal Amyloidosis: A Rare Complication of Atezolizumab. Cureus [Internet]. 27 nov 2023 [cité 20 févr 2024] Disponible ici | Lire le résumé |
| Ioannou A, Rauf MU, Patel RK, Razvi Y, Porcari A, Martinez‐Naharro A, et al. Albuminuria in transthyretin cardiac 26(1):65‑73 | Lire le résumé |
| Ait-Idir D, Djerdjouri B, Latreche K, Sari-Hamidou R, Khellaf G. Predicting genetic risk factors for AA amyloidosis in Algerian patients with familial Mediterranean fever. Mol Genet Genomics. déc 2024;299(1):25 | Lire le résumé |
| Karatemiz G, Esatoglu SN, Gurcan M, Ozguler Y, Yurdakul S, Hamuryudan V, et al. Frequency of AA amyloidosis has decreased in Behçet’s syndrome: a retrospective study with long-term follow-up and a systematic review. Rheumatology. 23 déc 2022;62(1):9‑18 | Lire le résumé |
| Basset M, Schönland SO, Obici L, Günther J, Riva E, Dittrich T, et al. Development and Validation of Staging Systems for AA Amyloidosis. J Am Soc Nephrol. 21 mars 2024 | Lire le résumé |
| Achaga X, Goena-Vives C, Villanueva-Benito I, Solla-Ruiz I, Rengel Jimenez A, Gaspar TI, et al. Development and Validation of a Prediction Model and Score for Transthyretin Cardiac Amyloidosis Diagnosis: T-Amylo. JACC Cardiovasc Imaging. déc 2023;16(12):1567‑80 | Lire le résumé |
| Kvacskay P, Hegenbart U, Lorenz HM, Schönland SO, Blank N. bDMARD can prevent the progression of AA amyloidosis to end-stage renal disease. Ann Rheum Dis. 23 avr 2024;ard-2023-225114 | Lire le résumé |
| Garcia-Pavia P, Sultan MB, Gundapaneni B, Sekijima Y, Perfetto F, Hanna M, et al. Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study. JACC Heart Fail. janv 2024;12(1):150‑60. | Lire le résumé |
| Ioannou A, Fumagalli C, Razvi Y, Porcari A, Rauf MU, Martinez-Naharro A, et al. Prognostic Value of a 6-Minute Walk Test in Patients With Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol. 2 juill 2024;84(1):43‑58. | Lire le résumé |
| Gioia G, Schrutka L, Jozwiak-Nozdrzykowska J, Kresoja KP, Gunold H, Klingel K, et al. Transthyretin amyloid cardiomyopathy among patients with heart failure and preserved ejection fraction: the AMY score. ESC Heart Fail. août 2024;11(4):2172‑81. | Lire le résumé |
| Basset M,Schönland SO, Obici L, Günther J, Riva E, Dittrich T, et al. Development and Validation of Staging Systems for AA Amyloidosis. JASN. juin 2024;35(6):782‑94. | Lire le résumé |
| 1. Papa R,Lachmann HJ. Secondary, AA, Amyloidosis. Rheum Dis Clin N Am [Internet]. nov 2018 [cité8sept2024];44(4):585‑603. 2. Vergneault H,Terré A, Buob D, Buffet C, Dumont A, Ardois S, et al. Amyloid Goiter in Familial Mediterranean Fever: Description of 42 Cases from a French Cohort and from Literature Review. J Clin Med [Internet]. 5 mai 2021 [cité 8 sept 2024];10(9):1983. | Lire le résumé |
| Charalampous C,Dasari S, McPhail E, Theis JD, Vrana JA, Dispenzieri A, et al. A proteomic atlas of kidney amyloidosis provides insights into disease pathogenesis. Kidney Int. mars 2024;105(3):484‑95 | Lire le résumé |